Population pharmacokinetics of carbamazepine in adults with epilepsy [Farmacocinética poblacional de carbamacepina en pacientes epilépticos adultos]
Article
Overview
Research
Identity
Additional Document Info
View All
Overview
abstract
The aim of the present study was to determinate the factors affecting carbamazepine (CBZ) clearance (CL) in adults with epilepsy using a mixed-effect model and sparse data collected during routine clinical care. The patient population comprised 104 adults receiving CBZ. A total of 161 CBZ steady state serum concentration samples were analyzed. Population CL was calculated by using NONMEM with a one compartment model with first-order absorption and elimination. The following covariates were tested for their influence on clearance (CL): total body weight, age, dose/day, sex, surface area (SA) and comedication with primidone (PRIM), valproic acid or phenytion (DFH). The final regression model for carbamazepine clearance found best to describe the data was: CL = (0.614 SA 0.0016 dose/day)(1 0.278 DFH)(1 0.326 PRIM).
The aim of the present study was to determinate the factors affecting carbamazepine (CBZ) clearance (CL) in adults with epilepsy using a mixed-effect model and sparse data collected during routine clinical care. The patient population comprised 104 adults receiving CBZ. A total of 161 CBZ steady state serum concentration samples were analyzed. Population CL was calculated by using NONMEM with a one compartment model with first-order absorption and elimination. The following covariates were tested for their influence on clearance (CL): total body weight, age, dose/day, sex, surface area (SA) and comedication with primidone (PRIM), valproic acid or phenytion (DFH). The final regression model for carbamazepine clearance found best to describe the data was: CL = (0.614 SA %2b 0.0016 dose/day)(1 %2b 0.278 DFH)(1 %2b 0.326 PRIM).
